CN1276754C - 胃肠基质肿瘤的治疗 - Google Patents

胃肠基质肿瘤的治疗 Download PDF

Info

Publication number
CN1276754C
CN1276754C CNB018178952A CN01817895A CN1276754C CN 1276754 C CN1276754 C CN 1276754C CN B018178952 A CNB018178952 A CN B018178952A CN 01817895 A CN01817895 A CN 01817895A CN 1276754 C CN1276754 C CN 1276754C
Authority
CN
China
Prior art keywords
treatment
patients
salt
acid
gist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB018178952A
Other languages
English (en)
Chinese (zh)
Other versions
CN1622808A (zh
Inventor
E·布赫恩格尔
R·卡普德维尔
G·D·德梅特瑞
S·迪米特里耶维奇
B·J·德鲁克尔
J·A·佛莱彻
H·约恩苏
S·L·西尔贝曼
D·图韦森
M·C·海因里西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
The Brigham and Women's Hospital Inc
Dana Farber Cancer Institute Inc
Oregon Health & Science University
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1276754(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1622808A publication Critical patent/CN1622808A/zh
Application granted granted Critical
Publication of CN1276754C publication Critical patent/CN1276754C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
CNB018178952A 2000-10-27 2001-10-26 胃肠基质肿瘤的治疗 Ceased CN1276754C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27

Publications (2)

Publication Number Publication Date
CN1622808A CN1622808A (zh) 2005-06-01
CN1276754C true CN1276754C (zh) 2006-09-27

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018178952A Ceased CN1276754C (zh) 2000-10-27 2001-10-26 胃肠基质肿瘤的治疗

Country Status (25)

Country Link
US (1) US6958335B2 (enExample)
EP (1) EP1332137B1 (enExample)
JP (1) JP4386635B2 (enExample)
KR (1) KR100885129B1 (enExample)
CN (1) CN1276754C (enExample)
AT (1) ATE321556T1 (enExample)
AU (2) AU1826202A (enExample)
BR (1) BRPI0114870B8 (enExample)
CA (1) CA2424470C (enExample)
CY (1) CY1105055T1 (enExample)
CZ (1) CZ303944B6 (enExample)
DE (1) DE60118430T2 (enExample)
DK (1) DK1332137T3 (enExample)
ES (1) ES2260317T3 (enExample)
HU (1) HU229106B1 (enExample)
IL (2) IL155029A0 (enExample)
MX (1) MXPA03003703A (enExample)
NO (1) NO324948B1 (enExample)
NZ (1) NZ525254A (enExample)
PL (1) PL209733B1 (enExample)
PT (1) PT1332137E (enExample)
RU (1) RU2301066C2 (enExample)
SK (1) SK287335B6 (enExample)
WO (1) WO2002034727A2 (enExample)
ZA (1) ZA200302155B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
PT1401416E (pt) * 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004530730A (ja) * 2001-06-29 2004-10-07 アブ サイエンス 腫瘍の血管新生を治療するための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用法
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
EP1461032B1 (en) * 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
PT1478380E (pt) * 2002-02-27 2006-12-29 Ab Science Utilização de inibidores de tirosina-cinases para tratar doenças do snc
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
IN2015MN00408A (enExample) 2012-07-27 2015-09-04 Antonius Martinus Gustave Bunt
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6525072B1 (en) * 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
ZA200302155B (en) 2004-04-22
BRPI0114870B8 (pt) 2021-05-25
IL155029A0 (en) 2003-10-31
PL362148A1 (en) 2004-10-18
EP1332137A2 (en) 2003-08-06
CA2424470C (en) 2009-06-09
DE60118430D1 (de) 2006-05-18
SK287335B6 (sk) 2010-07-07
PL209733B1 (pl) 2011-10-31
BR0114870A (pt) 2004-02-17
AU2002218262B2 (en) 2005-09-29
NO20031833L (no) 2003-04-24
IL155029A (en) 2009-09-22
HK1058193A1 (en) 2004-05-07
KR20030051656A (ko) 2003-06-25
KR100885129B1 (ko) 2009-02-23
CZ303944B6 (cs) 2013-07-10
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
SK5182003A3 (en) 2004-02-03
DE60118430T2 (de) 2006-10-26
ATE321556T1 (de) 2006-04-15
HUP0301512A2 (hu) 2003-11-28
CN1622808A (zh) 2005-06-01
NO324948B1 (no) 2008-01-07
WO2002034727A2 (en) 2002-05-02
EP1332137B1 (en) 2006-03-29
RU2301066C2 (ru) 2007-06-20
US20040023976A1 (en) 2004-02-05
ES2260317T3 (es) 2006-11-01
BRPI0114870B1 (pt) 2020-06-16
NZ525254A (en) 2006-02-24
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
HU229106B1 (en) 2013-07-29
JP4386635B2 (ja) 2009-12-16
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
MXPA03003703A (es) 2005-01-25
DK1332137T3 (da) 2006-07-17
CZ20031152A3 (en) 2004-04-14
CY1105055T1 (el) 2010-03-03
AU1826202A (en) 2002-05-06

Similar Documents

Publication Publication Date Title
JP4386635B2 (ja) 消化管間質腫瘍の処置
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
AU2019328903B2 (en) Composition for eradicating Helicobacter pylori
US9827211B2 (en) Uses and methods for the treatment of liver diseases or conditions
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
HK1058193B (en) Treatment of gastrointestinal stromal tumors
CN121401261A (zh) 喹诺林化合物治疗甲状腺癌的用途
CN117899071A (zh) 一种治疗恶性脑胶质瘤的小分子药物及其应用
CN105560236B (zh) 一种含有银杏内酯b和非肽类凝血酶抑制剂的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DANA FARBER CANCER INST INC. UNIV OREGON HEALTH +

Effective date: 20111220

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20111220

Address after: Basel

Co-patentee after: Dana Farber Cancer Institute Inc.

Patentee after: Novartis AG

Co-patentee after: Univ Oregon Health & Science

Co-patentee after: Brigham and Women's Hospital

Address before: Basel

Patentee before: Novartis AG

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Patentee after: Dana Farber Cancer Institute Inc.

Patentee after: Univ Oregon Health & Science

Patentee after: Brigham and Women's Hospital

Address before: Basel

Patentee before: Novartis AG

Patentee before: Dana Farber Cancer Institute Inc.

Patentee before: Univ Oregon Health & Science

Patentee before: Brigham and Women's Hospital

IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20151126

Decision number of declaring invalidation: 27371

Granted publication date: 20060927

IW01 Full invalidation of patent right